Knockdown of TFIIS by RNA silencing inhibits cancer cell proliferation and induces apoptosis.

Kyle Hubbard, Jennifer Catalano, Raj K Puri, Averell Gnatt
Author Information
  1. Kyle Hubbard: Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, MD 21201, USA. hubbard.kyle@gmail.com

Abstract

BACKGROUND: A common element among cancer cells is the presence of improperly controlled transcription. In these cells, the degree of specific activation of some genes is abnormal, and altering the aberrant transcription may therefore directly target cancer. TFIIS is a transcription elongation factor, which directly binds the transcription motor, RNA Polymerase II and allows it to read through various transcription arrest sites. We report on RNA interference of TFIIS, a transcription elongation factor, and its affect on proliferation of cancer cells in culture.
METHODS: RNA interference was performed by transfecting siRNA to specifically knock down TFIIS expression in MCF7, MCF10A, PL45 and A549 cells. Levels of TFIIS expression were determined by the Quantigene method, and relative protein levels of TFIIS, c-myc and p53 were determined by C-ELISA. Induction of apoptosis was determined by an enzymatic Caspase 3/7 assay, as well as a non-enzymatic assay detecting cytoplasmic mono- and oligonucleosomes. A gene array analysis was conducted for effects of TFIIS siRNA on MCF7 and MCF10A cell lines.
RESULTS: Knockdown of TFIIS reduced cancer cell proliferation in breast, lung and pancreatic cancer cell lines. More specifically, TFIIS knockdown in the MCF7 breast cancer cell line induced cancer cell death and increased c-myc and p53 expression whereas TFIIS knockdown in the non-cancerous breast cell line MCF10A was less affected. Differential effects of TFIIS knockdown in MCF7 and MCF10A cells included the estrogenic, c-myc and p53 pathways, as observed by C-ELISA and gene array, and were likely involved in MCF7 cell-death.
CONCLUSION: Although transcription is a fundamental process, targeting select core transcription factors may provide for a new and potent avenue for cancer therapeutics. In the present study, knockdown of TFIIS inhibited cancer cell proliferation, suggesting that TFIIS could be studied as a potential cancer target within the transcription machinery.

References

  1. Blood. 2005 Oct 1;106(7):2513-9 [PMID: 15972445]
  2. J Biol Chem. 2001 Aug 24;276(34):31793-9 [PMID: 11431468]
  3. Nucleic Acids Res. 1999 Aug 1;27(15):3173-82 [PMID: 10454615]
  4. BMC Dev Biol. 2005 Oct 05;5:22 [PMID: 16207381]
  5. Apoptosis. 2003 Jan;8(1):55-60 [PMID: 12510152]
  6. Cancer Res. 2006 Feb 15;66(4):2059-66 [PMID: 16489005]
  7. J Biol Chem. 1995 Dec 1;270(48):28507-10 [PMID: 7499360]
  8. Mol Cancer Ther. 2004 Sep;3(9):1079-90 [PMID: 15367702]
  9. Angiogenesis. 2005;8(4):361-72 [PMID: 16400518]
  10. Trends Biochem Sci. 1996 Sep;21(9):351-5 [PMID: 8870500]
  11. Oncogene. 2006 Apr 13;25(16):2328-38 [PMID: 16314837]
  12. Science. 2002 Jul 5;297(5578):102-4 [PMID: 12098700]
  13. Blood. 1999 Mar 15;93(6):1980-91 [PMID: 10068671]
  14. Clin Chem. 2006 Jul;52(7):1294-302 [PMID: 16709626]
  15. Yeast. 1996 Mar 15;12(3):227-36 [PMID: 8904334]
  16. Breast. 2005 Dec;14(6):624-30 [PMID: 16202599]
  17. Cell Mol Biol Res. 1993;39(4):331-8 [PMID: 8312968]
  18. J Biol Chem. 2005 Mar 25;280(12):11569-77 [PMID: 15653676]
  19. Mol Cell Biol. 2001 Jan;21(2):595-602 [PMID: 11134345]
  20. Cell Cycle. 2006 Oct;5(19):2191-4 [PMID: 17012843]
  21. Prog Cell Cycle Res. 2003;5:269-78 [PMID: 14593721]
  22. Histochem Cell Biol. 1997 Mar;107(3):259-63 [PMID: 9105897]
  23. Mol Cell Biol. 2006 Apr;26(8):3194-203 [PMID: 16581793]
  24. Ann Oncol. 2003 Aug;14(8):1270-3 [PMID: 12881391]
  25. Br J Cancer. 2003 Nov 3;89(9):1757-65 [PMID: 14583781]
  26. Mol Cell Biol. 1990 May;10(5):1915-20 [PMID: 2183013]
  27. Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6579-84 [PMID: 17420474]
  28. RNA Biol. 2005 Jan;2(1):17-20 [PMID: 17132935]
  29. J Biol Chem. 2002 Dec 27;277(52):50768-75 [PMID: 12372818]
  30. Nature. 2000 Aug 17;406(6797):747-52 [PMID: 10963602]
  31. Biochem J. 2003 Jun 1;372(Pt 2):631-41 [PMID: 12646044]
  32. Breast Cancer Res. 2001;3(2):77-80 [PMID: 11250749]
  33. Oncogene. 2005 Jun 30;24(28):4559-71 [PMID: 15856024]
  34. J Biol Chem. 2006 Feb 17;281(7):3876-88 [PMID: 16352606]
  35. Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9506-11 [PMID: 16769904]
  36. Biochim Biophys Acta. 2004 Mar 15;1677(1-3):87-99 [PMID: 15020050]
  37. Cancer Res. 2000 Nov 1;60(21):5922-8 [PMID: 11085504]
  38. Oncogene. 1999 Oct 14;18(42):5765-72 [PMID: 10523857]
  39. Cancer Res. 2000 Aug 1;60(15):4037-43 [PMID: 10945605]
  40. J Biol Chem. 1988 Sep 5;263(25):12705-8 [PMID: 3045126]
  41. RNA. 2004 Jan;10(1):12-8 [PMID: 14681580]
  42. Gene Ther. 2001 Nov;8(22):1705-12 [PMID: 11892838]
  43. Cell. 2004 Jan 23;116(2):259-72 [PMID: 14744436]
  44. Mol Cell Biol. 2003 Apr;23(7):2341-50 [PMID: 12640119]
  45. Science. 2006 Feb 10;311(5762):847-51 [PMID: 16469926]
  46. Oncogene. 1995 Jan 19;10(2):319-28 [PMID: 7838531]
  47. J Biol Chem. 1989 Jun 25;264(18):10799-809 [PMID: 2471707]
  48. Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1892-7 [PMID: 14769924]
  49. Biochemistry. 1990 Jan 9;29(1):269-78 [PMID: 2157481]
  50. Cell. 1997 Apr 4;89(1):33-41 [PMID: 9094712]
  51. Endocrinology. 1998 Jul;139(7):3050-6 [PMID: 9645675]
  52. Oncogene. 1997 Oct 16;15(16):1937-46 [PMID: 9365240]
  53. Eur J Cancer. 2004 Dec;40(18):2667-75 [PMID: 15571950]
  54. Clin Immunol. 2003 Oct;109(1):89-102 [PMID: 14585280]
  55. Oncogene. 1996 Aug 1;13(3):461-9 [PMID: 8760287]
  56. Gene Ther. 2006 Mar;13(6):464-77 [PMID: 16341059]
  57. Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6192-7 [PMID: 11972069]
  58. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11552-7 [PMID: 8876173]
  59. Oncogene. 1999 Jan 21;18(3):583-92 [PMID: 9989808]
  60. Adv Cancer Res. 2002;84:81-154 [PMID: 11885563]
  61. Int J Biol Markers. 2003 Jan-Mar;18(1):54-6 [PMID: 12699064]
  62. J Biol Chem. 2001 Jun 22;276(25):23109-14 [PMID: 11259417]
  63. BMC Genomics. 2003 Jun 12;4(1):23 [PMID: 12803655]
  64. Endocrinology. 2002 Jun;143(6):2093-105 [PMID: 12021174]
  65. J Biol Chem. 2007 Feb 16;282(7):4243-4252 [PMID: 17130135]
  66. Oncogene. 2001 May 28;20(24):3116-27 [PMID: 11420728]
  67. Cancer Genet Cytogenet. 2005 Nov;163(1):23-9 [PMID: 16271952]
  68. Biotechniques. 2002 Dec;33(6):1244-8 [PMID: 12503308]
  69. Mol Cell Biol. 1988 Oct;8(10):4389-94 [PMID: 3054517]
  70. CRC Crit Rev Biochem. 1978 Dec;5(3):185-260 [PMID: 363352]

Grants

  1. R01 GM064474/NIGMS NIH HHS
  2. GM64474/NIGMS NIH HHS

MeSH Term

Apoptosis
Breast Neoplasms
Cell Growth Processes
Cell Line, Tumor
Humans
Lung Neoplasms
Neoplasms
Pancreatic Neoplasms
Proto-Oncogene Proteins c-myc
RNA Interference
RNA, Messenger
RNA, Small Interfering
Transcriptional Elongation Factors
Transfection
Tumor Suppressor Protein p53

Chemicals

MYC protein, human
Proto-Oncogene Proteins c-myc
RNA, Messenger
RNA, Small Interfering
TP53 protein, human
Transcriptional Elongation Factors
Tumor Suppressor Protein p53
transcription factor S-II

Word Cloud

Created with Highcharts 10.0.0TFIIScancertranscriptioncellcellsMCF7RNAproliferationMCF10Aknockdownexpressiondeterminedc-mycp53breastmaydirectlytargetelongationfactorinterferencesiRNAspecificallyC-ELISAapoptosisassaygenearrayeffectslinesKnockdownlineBACKGROUND:commonelementamongpresenceimproperlycontrolleddegreespecificactivationgenesabnormalalteringaberrantthereforebindsmotorPolymeraseIIallowsreadvariousarrestsitesreportaffectcultureMETHODS:performedtransfectingknockPL45A549LevelsQuantigenemethodrelativeproteinlevelsInductionenzymaticCaspase3/7wellnon-enzymaticdetectingcytoplasmicmono-oligonucleosomesanalysisconductedRESULTS:reducedlungpancreaticinduceddeathincreasedwhereasnon-cancerouslessaffectedDifferentialincludedestrogenicpathwaysobservedlikelyinvolvedcell-deathCONCLUSION:Althoughfundamentalprocesstargetingselectcorefactorsprovidenewpotentavenuetherapeuticspresentstudyinhibitedsuggestingstudiedpotentialwithinmachinerysilencinginhibitsinduces

Similar Articles

Cited By